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Abstract
Background: Children carry most of the schistosomiasis burden. While school-aged children are the principal
target group of preventive chemotherapy with praziquantel, limited information on efficacy and safety exists
for preschool-aged children.
Methods: Here, we conducted a meta-analysis of clinical trials of praziquantel for treating children with any form of
schistosomiasis. Efficacy was reported as cure rate (CR) and egg reduction rates (ERR); statistical corrections were
applied based on methodological disparities across trials to derive the predicted geometrical mean ERR (pERRgm).
Safety was reported as frequencies of adverse events.
Results: Forty-seven comparative and non-comparative studies were identified, enrolling 15,549 children of
whom 14,340 (92%) were assessed between 3 and 8 weeks post-treatment with praziquantel 40 mg/kg (the
WHO-recommended treatment, n = 8,380, 56%) or comparators (n = 5,960, 44%). The median age was 10 years
(range 1–19), 11% (n = 1,694) were preschool-aged. The CR and pERRgm with praziquantel 40 mg/kg were
respectively: S. haematobium, 73.6% (95% CI: 63.5–81.40, 25 study arms) and 94.7% (95% CI: 92.7–96.4); S. mansoni,
76.4% (95% CI: 71.5–81.0, 34 arms) and 95.3% (95% CI: 94.2–96.2); S. mansoni/S. haematobium, 67.6% (95% CI: 54.1–80.7,
5 arms) and 93.4% (95% CI: 89.9–96.2); S. japonicum, 94.7% (95% CI: 92.2–98.0) and 98.7% (95% CI: 98.3–99.2).
Mixed-effect multivariate analysis found no significant difference between preschool- and school-aged children for CR
or pERRgm in S. haematobium (P = 0.309 and P = 0.490, respectively) or S. mansoni (P = 0.982 and P = 0.895) after
controlling for time of assessment, formulation, intensity of infection and detection method. Praziquantel was
reportedly safe at all ages, with only mild reported adverse events which cleared rapidly after treatment.
Conclusions: Praziquantel 40 mg/kg was effective at reducing infection intensity in all Schistosoma species without
differences between preschool- and school-aged children. However, conclusions should be tempered because of the
limited number of preschool-aged children enrolled, disparities in study procedures and limited information made
available in publications, as well as the current imperfect test-of-cure. Also, although reportedly well-tolerated, safety
was inconsistently assessed. Studies in target groups, individual-data meta-analysis and standardised methodologies
are needed for more robust evidence-base.
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Background
Children carry most of the schistosomiasis burden [1].
Schistosomiasis treatment and control relies largely upon
preventive chemotherapy (PC) with praziquantel (PZQ)
directed primarily at school-aged children living in
schistosomiasis-endemic areas [2]. Preschool-aged chil-
dren have traditionally been excluded from PC and treated
on confirmation of infection [3], but are recognized as a
vulnerable group [4–6]. Emphasis is now shifting from
control to elimination of schistosomiasis [7], meaning that
all the infected groups should be treated, including
preschool-aged children (1–4 years-old), provided a
suitable formulation is available. PZQ is registered for
use in children from four years of age, and can be given
routinely in PC programmes to children measuring
94 cm or more (recently extended to 60 cm [8]) but the
absence of paediatric formulations is a practical limita-
tion to having younger children treated routinely.
Praziquantel has been in use now for over three de-
cades, and has been given to millions of people, mostly
children - close to 40 million school-aged children in
2013 [9]. However, several unresolved questions still
exist about this drug (reviewed in Stothard et al. [10]),
including its pharmacokinetic and pharmacodynamic
properties [11].
The World Health Organization (WHO) recommends
using PZQ at 40 mg/kg, a recommendation generally
supported by systematic reviews [12–14] and to express
treatment outcome in terms of egg reduction rate (ERR)
calculated as the difference of the arithmetic mean egg
counts (preferred over geometric means) between pre-
and post-treatment samples [3]. It is worth adding, as a
note of caution, that we only have imprecise methods to
detect Schistosoma infection that are based on the detec-
tion of eggs in excreta (faeces or urine) as opposed to
adult worms, and that these methods lack sensitivity (for
instance, the widely-used Kato-Katz method cannot
detect less than 24 eggs per gram of stools). Therefore,
the (temporary) reduction or cessation of egg-excretion
should not be interpreted as being equivalent to killing
of adult worms. This has profound implications both for
the estimation of schistosomiasis cases and for the
assessment of drug efficacy [15].
This meta-analysis was conducted to assess the effi-
cacy and safety of PZQ in preschool- and school-aged
children and whether these outcomes differ with sub-
ject’s age. This question is particularly relevant in view
of the inclusion of preschool-aged children as a target of
schistosomiasis control through PC, and whether any
dose adjustment should be required.
Methods
This is a meta-analysis of aggregated data; eligible studies
were comparative and non-comparative clinical trials
where PZQ had been given at any dose to preschool- and
school-aged children and adolescents) for treating intes-
tinal or urinary schistosomiasis, and where outcome was
assessed within 2 months (3 to 8 weeks) post-treatment.
The study was conducted according to the PRISMA
guideline (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) [16]. The PRISMA checklist
was used to ensure inclusion of relevant information in
the analysis (Additional file 1: Table S1).
Published studies were identified by the Cochrane col-
laboration through electronic searches from January 1,
1990, up to November 2015 of MEDLINE, EMBASE,
LILACS, the Cochrane Infectious Diseases Group’s trials
register and the Cochrane Central Register of Controlled
Trials (CENTRAL) using the search term “praziquantel”,
regardless of language (English, French, and Portuguese)
and might have failed to identify articles published in
other languages.
To qualify for inclusion, trials were to be on PZQ
mono-therapy at any dosage and dosing regimen, using
any formulation and brand, and could be either non-
comparative or comparative (randomized controlled
trial, quasi-randomised trials). The search identified 828
studies of PZQ in schistosomiasis in children, of which
47 had an assessment within 8 weeks (subjects treated
with praziquantel, control treatment or placebo). A pre-
vious paper reported the results of a broader meta-
analysis conducted up to 2012 including subjects of all
ages [14].
Efficacy outcomes are reported as cure rate (CR) and
egg reduction rate (ERR). CR, defined as the conversion
from a positive test pre-treatment to a negative test up
to 8 weeks post-treatment, is reported as provided in the
articles on a per-protocol population. ERR, defined as
the proportional reduction in the mean eggs per gram of
faeces (intestinal schistosomiasis) or per ml of urine
(urinary schistosomiasis) post-treatment vs pre-treatment
is presented based on the arithmetic (ERRam) or geo-
metric (ERRgm) mean ERR provided in the articles, re-
spectively, 5 and 31 of the studies included in this
review (11 studies did not report ERR). Since ERR was
inconsistently assessed on all patients in the per-
protocol population or only those who had countable
eggs in their excreta post-treatment (‘uncured’), a loga-
rithmic correlation between the CR and the ERRgm
(log-transformed) was applied to correct the ERRgm
results based on uncured patients and to help predict
the ERRgm in studies that reported only the CR.
Tolerability is assessed by calculating the incidence of
adverse events (AE) defined as any sign or symptom
occurring after treatment, irrespective of whether that
sign or symptom was present at baseline or not, of its
severity and drug-event relationship. The mean inci-
dence is presented for the PZQ 40 mg/kg treatment
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groups (all brands) excluding PZQ 40 mg/kg syrup, and
Levo-PZQ 20 mg/kg.
The 95% confidence intervals (CI) for the mean CR,
ERR, and AE are calculated using a bootstrap resampling
method based on statistical bias between studies with a
maximum of 1,000 replicates [17]. For randomized con-
trolled trials assessing the efficacy (CR) and tolerability
(AE) of PZQ vs other drugs, placebo, or comparing dif-
ferent PZQ dosing regimens, risk ratios (RR) with 95%
CI, meta-analysis regression with random effect on the
study/site is used and the pooled RR is presented using
the DerSimonian & Laird procedure for random effects
models [18]. Heterogeneity was expressed as I2 [19].
Children’s age groups were differently categorized
whether the study was school-based (between 5 and
17 years of age) or community based including (i)
preschool-aged (between 1 and 5 or 7 years) and (ii)
school-aged (between 4 and 19 years) according to
study definition. It should be noted that studies used
categories which only partly conform with the WHO
age classification for PC: preschool-aged 1–4-year-old;
school-aged children 5–14-year-old.
Age-groups were inconsistently defined and generally
broader in community-based studies; for example, chil-
dren in nursery were enrolled as school-aged in a commu-
nity based study [20]. As the studies had disparate age
ranges, a median age (in year) was calculated from the
reported range. A multivariate mixed-effect model was
used to assess the age-dependency of CR and ERR with
random effect on the site in an attempt to account for any
potential statistical heterogeneity across studies while con-
trolling for potential confounders such as: (i) endpoint of
assessment (analysed as a continuous variable, in week);
(ii) differences in diagnostic approaches (binary, single vs
multiple smears); (iii) infection intensities before treat-
ment, categorized as light (<100 egg per gram of faeces),
moderate (100–399), and heavy (≥400) for S. mansoni,
and categorized as light (<50 eggs/10 ml urine) and heavy
(≥50) for S. haematobium; (iv) year of study.
Graphical displays for CR and ERR by age group were
illustrated using forest plots [21]. Data were analysed
using Stata v13 (Stata Corp.).
We also provide more detailed narrative summaries of
the studies treating specifically preschool-aged children
and those reporting results for narrower age-groups,
where more direct comparisons are possible between
more homogenous populations.
Results
This analysis is based on 47 studies [20, 22–67] enrolling
15,549 children aged 6 months to 19 years (of whom
1,694 (11%) were preschool-aged children). Of these
14,340 were assessed for efficacy between 3 and 8 weeks
after treatment (8% attrition, acceptable risk of attrition
bias) (Table 1, Additional file 2: Table S2) of whom 11%
(n = 1,506) were preschool-aged (5 studies) and 89%
(n = 12,834) school-aged (42 studies), 48% (n = 6,897)
infected with S. mansoni, 39% (n = 5,552) with S. haemato-
bium, 8% (n = 1,196) with S. japonicum, and 5% (n = 695)
co-infected with S. mansoni/S. haematobium. Fifty-eight
percent (58%, n = 8,380) of the subjects were treated with
PZQ 40 mg/kg (tablets, n = 8,037 or syrup, n = 343), 14%
(n = 2,013) with other doses of PZQ, and 30% (n = 4,302)
with other drugs or placebo. Outcomes were measured
within 4 weeks post-treatment in 56% (n = 8,042) and
within 4 to 8 weeks in 44% (n = 6,298) of the children. No
study enrolled both preschool- and school-aged children.
The 1,694 pre-school-aged children were treated at
five sites in Uganda, Niger and Ivory Coast with PZQ
40 mg/kg (tablet or syrup) or PZQ 2*40 mg/kg for S.
mansoni and S. haematobium. The attrition at the one-
month post-treatment assessment was 11%. Of the 1,506
children assessed, 12% (n = 179) were infected with S.
haematobium and were either treated with PZQ 40 mg/
kg tablet in a single-arm study (n = 18) [22] or with
syrup only also in a single-arm study (n = 161) [23] and
88% (n = 1,327) were infected with S. mansoni: a two-
arm study comparing crushed tablets and syrup, both
given at 40 mg/kg (n = 203) [24]; a two-arm study [25]
comparing PZQ tablets given as a single dose of 40 mg/kg
(n = 357) to a double-dose of 2*40 mg/kg (n = 339);
two single-arm studies [22, 26] with crushed tablets
only (n = 369 and 35, respectively); and a single-arm
study (with syrup only; n = 88) [23].
Treatment outcome was reported as CR in 14,157
children and as ERR (all calculations methods) in
10,033 patients overall, of whom 58% (n = 8,199) and
62% (n = 5,958), respectively, were treated with PZQ
40 mg/kg (Fig. 1). The breakdown by species and reported
outcome was: both CR and ERR, 62% of the subjects; CR
only, 33%; and ERR only, 5%. For S. haematobium, the
outcome was reported as CR for 4,612 patients and
3,963 for ERR; for S. mansoni this was 6,897 and 5,138,
respectively; for S. mansoni/S. haematobium, 695 and
111; and for S. japonicum, 1,196 and 403.
Of the 36 studies reporting outcomes as ERR, 31 used
the ERRgm and 5 the ERRam (2 studies reported both)
(Table 2). The ERRgm was calculated using a log-
transformation applied to the entire per-protocol popu-
lation for 24% of subjects, on uncured patients only in
16%, and not specified in 26%. No study reported
ERRam on uncured subjects.
Egg counts were reported using different diagnostic
approaches (number of specimens and tests): from one
to three days and one to three stools per day tested in
simple or duplicate or triplicate slides. The most frequent
approach for S. mansoni was one test on one stool sample
collected on the same day and for S. haematobium was
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one test on two separate urine samples, collected on the
same day. Subjects receiving PZQ 40 mg/kg for S.
mansoni had a mean egg count before treatment of 376
eggs per gram of faeces (epg, range 1.2–2,662); the
mean was higher in studies using arithmetic means
(854, range 144–2,662 epg) than those using geometric
means (276, range 1.2–1,065 epg); for S. haematobium
105 eggs per ml of urine (range 1–630), also higher with
arithmetic than geometric means (120 and 108, respect-
ively); and for S. japonicum, mean epg 297 (range 60–255;
studies reporting only geometric means).
Efficacy of PZQ 40 mg/kg
The calculated median age of the total 8,380 subjects
treated with the PZQ 40 mg/kg was 9 years (range
1 month to 19 years) and clustered around 6 to 15 years
of age. The median age of school-children varied widely
across sites from 4 to 19 years, mostly depending on
whether the study was school- or community-based.
The overall CR in children treated with PZQ 40 mg/kg
(tablet and syrup) was 73.6% (95% CI: 64.1–82.3, 25
study groups, 3,294 children) for S. haematobium and
76.4% (95% CI: 71.5–81.0, 34 groups, 4,157 children) for
S. mansoni (Fig. 2). The overall reported ERRgm for S.
haematobium was 90.9% (95% CI: 86.0–95.6, 21 groups,
2,586 children) but was 81.0% for ERR based on uncured
patients and 99.5% for ERRgm log-transformed; for S.
mansoni it was 84.3% (95% CI: 79.0–89.3, 22 groups,
3,233 children), from 79.7% for ERR based on uncured
patients to 92.0% for ERRgm log-transformed. For S.
Fig. 1 Flow chart of studies and patients
Table 2 Methods used in the studies to calculate egg reduction rate (ERR). Seven studies not presented in the table assessed S.
japonicum or S. haematobium/S. mansoni







Total S. haematobium S. mansoni
n % n % n % n % n %
ERRgm log-transformed 3,670 24 3,475 32 9 19 6 33 3 14
ERRam 881 6 715 7 5 11 2 11 3 14
ERRgm method unclear 3,980 26 3,790 23 12 26 4 22 6 27
ERRgm calculated on uncured 2,444 16 2,066 14 10 21 3 17 5 23
No ERR 4,574 29 4,294 30 11 23 3 17 5 23
Total 15,549 100 14,340 100 47 100 18 100 22 100
Abbreviations: ERRam egg reduction rate calculated using arithmetic mean, ERRgm egg reduction rate using geometric mean
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japonicum the CR was 94.7% (95% CI: 92.1–98.0, three
groups, 406 children) and the ERRgm was 95.0% (95%
CI: 90.1–99.9, one study, 203 children); in mixed S. hae-
matobium/S. mansoni infections, the CR was 67.6% (95%
CI: 53.6–82.4, three studies, 342 children) and the ERRgm
98.0% (95% CI: 90.9–99.9, one study, 54 children).
Using the reported CR and ERRgm with log-
transformation calculation from 34 study arms (Fig. 3),
a logarithmic correlation was found (y = 0.158 ln(x) +
0.995, R2 = 0.34) with which we extrapolated the corre-
sponding predicted ERRgm (pERRgm) for all PZQ
groups, whatever the original calculation method. As a
result, in PZQ 40 m/kg groups, the overall pERRgm
was 94.7% (95% CI: 92.7–96.4) for S. haematobium,
95.3% (95% CI: 94.2–96.2) for S. mansoni, 93.4% (95%
CI: 89.9–96.2) for S. mansoni/S. haematobium, and
98.7% (95% CI: 98.3–99.2) for S. japonicum (Table 3).
The ratio between predicted and reported log-
transformed ERRs averaged 1.1 (0.93–1.4). The sensitivity
analysis restricted to the studies reporting log-
transformed ERRgm showed that the pERRgm was on
average 0.8% higher than the reported ERRgm (using
logarithmic transformation). Similarly, the pERRgm was
on average 24% higher than the reported ERRgm based
on uncured patients, 12% higher than the reported
ERRgm with unspecified method and 3% higher than
the reported ERRam.
Based on reported ERRs (all methods), 45% (26/47) of
the study arms treated with PZQ 40 mg/kg for any species
would not meet the 90% ERR threshold, compared to 15%
(7/47) after statistical correction (Additional file 3:
Table S3).
Efficacy of PZQ 40 mg/kg by species and age groups
Schistosoma haematobium
The CR was 87.3% (95% CI: 85.7–88.9, 2 groups) in
preschool-aged children, and 71.4% (95% CI: 62.3–80.5,
22 groups) in school-aged children; the pERRgm was
Fig. 2 Cure rate (CR) by age group and Schistosoma species, PZQ 40 mg/kg. Abbreviations: sh, S. haematobium; sj, S. japonicum; sm, S. mansoni
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97.1% (95% CI: 97.1–97.7) and 94.4% (95% CI: 92.4–96.3),
respectively. The mixed-effect model did not detect any
difference in CR or pERRgm between preschool- and
school-aged children (P = 0.309, P = 0.490, respectively),
syrup and tablet formulation (P = 0.925, P = 0.949), week
of assessment (P = 0.287, P = 0.337), light vs more intense
infection (P = 0.199, P = 0.086), one vs multiple samples
(P = 0.723, P = 0.660).
Schistosoma mansoni
The CR was 82.0% (95% CI: 72.6–90.0, 9 groups) in
preschool-aged children, and 74.4% (95% CI: 68.8–79.5,
25 groups) in school-aged children; the pERRgm was
96.4% (95% CI: 72.6–90.0) and 94.9% (95% CI: 93.6–95.9),
respectively. The mixed-effect model did not detect any
difference in CR or pERRgm between preschool- and
school-aged children (P = 0.982, P = 0.895, respectively),
syrup and tablet formulation (P = 0.956, P = 0.959), week
of assessment (P = 0.791, P = 0.784), light vs more intense
infection (P = 0.932, P = 0.837), one vs multiple samples
(P = 0.741, P = 0.631).
Schistosoma mansoni/S. haematobium
The CR was 71.9% (95% CI: 61.8–87.7) in school-aged
children under 10 years old in three studies, and 61.0%
(95% CI: 45.5–76.6) in older school-aged children in two
studies. The ERR was only recorded in one study for
under 10’s and was 98.0% (95% CI: 94.6–100). The over-
all CR was 67.6% (95% CI: 54.1–80.7, 5 groups) and the
corresponding pERRgm was 93.4% (95% CI: 89.9–96.2).
Using multivariate analysis, no correlation was detected
between age and CR (P = 0.625).
Schistosoma japonicum
The CR was 92.1% (95% CI: 86.8–97.4) in school-aged
children under 10 years old in one study, and 96.0%
(95% CI: 94.0–98.0) in older schoolchildren in two studies.
The overall CR was 94.7% (95% CI: 92.2–98.0), the
reported ERR was 95.0% (95% CI: 90.1–99.9) and the
pERRgm was 98.7% (95% CI: 98.3–99.2).
PZQ 40 mg/kg vs comparators
In studies comparing PZQ 40 mg/kg to other PZQ
regimens for treating S. haematobium, and using
meta-analysis regression (Additional file 4: Figure S1),
no difference was detected vs PZQ 30 mg/kg (RR = 0.94,
95% CI: 0.87–1.01, P = 0.106) and split-dose PZQ
2*20 mg/kg (RR = 0.98, 95% CI: 0.94–1.04, P = 0.590);
subjects treated with PZQ 40 mg/kg were at a significantly
lower risk of failure than artesunate alone (RR = 0.54,
95% CI: 0.36–0.83, P = 0.005) or in combination (AS +
SP, RR = 0.83, 95% CI: 0.79–0.88, P = 0.001; AS +MQ,
RR = 0.69, 95% CI: 0.47–1.02, P = 0.066), mefloquine
alone (RR = 0.24, 95% CI: 0.10–0.58, P = 0.001); metrifo-
nate 10 mg/kg (RR = 0.15, 95% CI: 0.04–0.58, P = 0.005),
albendazole (RR = 0.43, 95% CI: 0.30–0.61, P = 0.001).
There was no difference between PZQ 40 mg/kg and PZQ
60 mg/kg, P = 0.750; ASMQ+ PZQ, P = 0.906; PZQ +
MQ, P = 0.499; albendazole + PZQ 40 mg/kg, P = 0.561.
Only PZQ 40 mg/kg in combination with artesunate
performed better than PZQ 40 mg/kg (RR = 1.17, 95%
CI: 1.03–1.33, P = 0.019).
Similarly, patients treated with PZQ 40 mg/kg for S.
mansoni (Additional file 5: Figure S2), were at a signifi-
cantly lower risk of failure than lower doses of PZQ
(10 mg/kg, RR = 0.35, 95% CI: 0.22–0.55; 20 mg/kg,
Fig. 3 Correlation between cure rates (CR) and reported egg reduction rate using geometric mean with log-transformation (ERRgm)
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RR = 0.56, 95% CI: 0.41–0.75; 30 mg/kg, RR = 0.81, 95%
CI: 0.70–0.92); artesunate combined with SP (RR = 0.59,
95% CI: 0.46–0.75, P = 0.001) or artesunate with sulfa-
lene (RR = 0.21, 95% CI: 0.12–0.34, P = 0.001), mirazid
300 mg/kg (RR = 0.15, 95% CI: 0.06–0.35, P = 0.001),
albendazole (RR = 0.60, 95% CI: 0.43–0.84, P = 0.003),
arachidonic acid (RR = 0.72, 95% CI: 0.55–0.96, P = 0.023).
No difference was detected between PZQ 40 mg/kg for-
mulated as tablet or syrup (RR = 1.01, 95% CI: 0.88–1.15,
P = 0.884), PZQ 60 mg/kg (RR = 1.05, 95% CI: 0.98–1.12,
P = 0.141), PZQ 2*40 mg/kg (RR = 1.03, 95% CI: 0.96–
1.10, P = 0.401), PZQ 40 mg/kg + albendazole (RR = 1.01,
95% CI: 0.78–1.31, P = 0.921), PZQ + arachidonic acid
(RR = 1.29, 95% CI: 0.88–1.88, P = 0.193) and oxamni-
quine at 15, 30, 40, 50 mg/kg (P = 0.254, P = 0.744,
P = 0.080, P = 0.056, respectively).
No difference was detected in mixed S. mansoni/S.
haematobium infection between PZQ 40 mg/kg and
PZQ 10 mg/kg (RR = 0.15, 95% CI: 0.02–1.08, P = 0.060),
20 mg/kg (RR = 0.63, 95% CI: 0.35–1.15, P = 0.135),
30 mg/kg (RR = 0.87, 95% CI: 0.67–1.12, P = 0.278),
split dose 2*20 mg/kg (RR = 1.07, 95% CI: 0.88–1.31,
P = 0.494), and oltipraz 30 mg/kg (RR = 1.05, 95% CI:
0.92–1.19, P = 0.481).
No difference was detected in patients treated for S.
japonicum between PZQ 40 mg/kg and PZQ 60 mg/kg
(RR = 1.02, 95% CI: 0.97–1.07, P = 0.461) or PZQ
40 mg/kg + albendazole (RR = 0.99, 95% CI: 0.94–1.04,
P = 0.767).
Safety: adverse events (AEs)
Overall, 22 studies recorded AEs in 6,713 children. One
additional tolerability study was included [68] to the 21
studies considered for the efficacy analysis. The propor-
tion of children treated with PZQ 40 mg/kg was 67%
(n = 4,480), 22% of whom were preschool-aged (n = 980).
The syrup formulation was tested on half of the pre-
school aged children. Out of the three studies reporting
Table 3 Efficacy, cure rate (CR) and predicted egg reduction rate using geometric mean (pERRgm) by Schistosoma species by age











Reported CR Reported ERR Predicted ERR Ratio ERR
reported/
predicted
% 95% CI bootstrap % % 95% CI bootstrap
Lower Upper Lower Upper
sh Pre-school 40 1 18 88.9 74.4 99.9 98.0 97.7 94.9 99.5 1.00
syrup 40 1 161 85.7 80.3 91.1 69.4 97.1 96.1 98.1 1.40
Total 40 2 179 87.3 85.7 88.9 83.7 97.4 97.1 97.7 1.16
School-aged 30 2 84 82.7 71.0 94.3 96.5 94.1 98.6
40 23 3,159 72.4 63.6 81.2 90.9 94.4 92.4 96.3 1.04
60 2 77 64.8 63.6 65.9 92.7 92.4 93.0
Total 40 25 3,338 73.6 64.8 81.7 90.9 94.7 92.7 96.4 1.04
sm Pre-school 40 7 806 83.1 71.1 94.3 89.7 96.6 94.2 98.6 1.08
syrup pzq40 2 182 78.0 75.0 80.9 77.9 95.6 95.0 96.2 1.23
2*40 4 339 88.7 80.0 98.7 99.3 97.6 96.0 99.3 0.98
Total 40 9 988 82.0 72.6 89.9 83.1 96.4 94.5 97.9 1.16
School-aged 10 1 61 26.2 15.2 37.2 78.4 69.8 84.0
20 4 385 40.3 24.9 55.0 91.8 85.2 77.6 90.1 0.93
30 1 197 63.0 56.3 69.7 96.1 92.3 90.5 93.9 0.96
40 25 3,169 74.4 68.8 79.5 84.6 94.9 93.6 95.9 1.12
60 5 667 78.6 67.8 90.0 85.1 95.7 93.4 97.9 1.13
Total 40 34 4,157 76.4 71.5 81.0 84.3 95.3 94.2 96.2 1.13
sm + sh School-aged 10 2 73 11.2 4.2 18.1 64.9 49.5 72.6
20 2 61 38.4 36.7 40.0 84.4 83.7 85.1
30 2 72 51.8 31.4 72.2 89.2 81.3 94.4
40 5 342 67.6 54.1 80.7 98.0 93.4 89.9 96.2 0.95
sj School-aged 40 3 406 94.7 92.2 98.0 95.0 98.7 98.3 99.2 1.04
60 2 200 97.5 97.0 98.0 95.4 99.1 99.0 99.2 1.04
Abbreviations: ERR egg reduction rate, pERRgm predicted egg reduction rate using geometric mean, CR cure rate, CI confidence interval, sh S. haematobium, sj S.
japonicum, sm S. mansoni
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AEs, one compared PZQ 40 mg/kg tablet and syrup for-
mulation [24]. The two other studies were not compara-
tive: one tested PZQ 40 mg/kg tablet [22] and the other
one the PZQ 40 mg/kg liquid syrup formulation [23]. Five
thousand, nine hundred and twenty-six AEs were reported
within 48 h of treatment in PZQ 40 mg/kg recipients.
Most of the signs and symptoms recorded were gastro-
intestinal, neurological and dermatological.
On average 55.5% (95% CI: 39.4–78.2) of the 1,606
patients treated in 10 studies with PZQ 40 mg/kg expe-
rienced at least one of the AEs listed (Fig. 4). Signs and
symptoms were not sought systematically in all studies.
The incidence of AEs ranged from 6.1% for itching/rash
(studied in 10 studies) to 35.5% for drowsiness (studied
in 3 studies). In preschool-aged children in Uganda [18],
no significant difference was detected between PZQ
40 mg/kg tablet (n = 254) and syrup (n = 249) in 15 dif-
ferent signs or symptoms screened.
One study analyzed age trends in schoolchildren aged
between 6 and 19 years old [46]. Authors found more
AEs in older subjects (P = 0.008) and differences between
sites.
Summary of efficacy and safety finding in trials in
preschool-aged children: a narrative review
Five studies [16–20] enrolled the totality of the 1,694
preschool-aged children, of whom 89% (n = 1,506) were
assessed for efficacy, 988 for S. mansoni and 179 for S.
haematobium treated with PZQ 40 mg/kg (90% with
tablet formulation).
In Navaratnam et al. [24], 203 preschool-aged children
aged 1.5 to 5 years were randomly assigned to PZQ
Fig. 4 Adverse event incidence, preschool and school children, PZQ 40 mg/kg
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40 mg/kg (crushed) tablet or syrup formulation. The
pre-treatment arithmetic mean egg count was 317.6 in
the tablet group and 292.1 in the syrup group. No differ-
ence was detected between the syrup and tablet formula-
tions for CR (80.9 vs 81.7%) and ERRam (86.1 vs 89.0%).
There was a significant correlation between pre-
treatment infection intensity and efficacy when assessed
as CR: 88.6% in light, 74.5% in moderate and 67.4% in
heavy infection. Non-compliance to PZQ syrup was
11.1% (95% CI: 8.6–14.0) and that of PZQ tablet was
14.7% (95% CI: 12.0–18.0) with no significant difference
detected (OR = 1.33, 95% CI: 0.93–1.92, P =0.110). Infants
12 months of age were 20.3 times more likely (P = 0.001)
to react negatively to the syrup formulation than 5 year
olds. Amelioration of vomiting (OR = 1.65, P = 0.006) and
peri-rectal bleeding (OR = 1.40, P = 0.007) was signifi-
cantly higher with crushed PZQ tablet. The most common
AEs in both treatment arms were dizziness, drowsiness
and fatigue. This was the only study to report dizziness in
preschool-aged children, and the incidence seemed to be
higher than what reported in 13 studies in school-aged
children (Table 4).
In Sousa-Figueiredo et al. [26], 305 patients aged from
5 months to 7 years were treated for S. mansoni. The
overall pre-treatment egg count was 144.1 or 5.99 eggs
using the arithmetic and geometric mean respectively.
Children under 4 years-old had a lower CR (40.8%) and
ERRam (75.4%), than 4 to 7 years-old (60.8 and 82.9%,
respectively). Children with history of previous treat-
ment had a lower CR (41.7%) and ERRam (72.8%) than
treatment-naive children (77.6 and 92.1%, respectively).
PZQ tablets proved to be safe, with only mild, transient
reported adverse events. At the6-month and 12-month
follow-up times, the number of cases of dizziness,
sleepiness, fatigue, cramps, nausea, sweating and night
fevers post-treatment decreased significantly compared
to baseline. No symptom became more prevalent with
time.
In Nalugwa et al. [25], Ugandan preschool-aged children
aged from 12 to 60 months were randomized to receive
PZQ 40 mg/kg or 2*40 mg/kg tablets (2 weeks apart). By
week 4, no difference was detected between treatment for
CR (83.2 and 85.5%, P = 0.390, respectively) or ERRgm
(98.9 and 99.3%, respectively). Efficacy was lower in
children with higher infection intensity and higher in
younger children.
Two studies treated preschool-aged children for S.
mansoni and S. haematobium with PZQ 40 mg/kg tablet
(Côte d’Ivoire, n = 53 [16]) and syrup (Niger, up to
67 months, n = 249 [17]). In Côte d’Ivoire the reported
efficacy was high against both S. mansoni (CR, 88.6%;
ERR, 96.7%) and S. haematobium (CR, 88.9%; ERR,
98.0%); in Niger, the reported efficacy was comparatively
lower for both S. haematobium (CR, 85.7%; ERR, 69.4%)
and S. mansoni (CR, 75.0%; ERR, 66.7%). Both trials
reported only mild AEs (only one case of face and body
inflammation that was graded as a moderately severe,
[16]) and no serious AE.
Discussion
This analysis is based on a systematic review of com-
parative and non-comparative studies of PZQ for treating
intestinal and urinary schistosomiasis, and concentrates
on the efficacy and safety of the WHO-recommended
standard dose of 40 mg/kg in preschool- and school-aged
children. The main question that we attempted to answer
was whether efficacy varied with the subject’s age, and
more specifically if PZQ at 40 mg/kg is as effective in
preschool-aged children as in older children, so that it can
be used more broadly in this younger age category. These
analyses do not indicate any age-effect on efficacy,
whether expressed as CR or ERRgm, or a dose-effect
Table 4 Adverse event incidence by age group, PZQ 40 mg/kg












% Lower bound Upper bound % Lower bound Upper bound
Any adverse event (at least one) 1 243 34.2 28.2 40.2 8 1,342 54.2 37.0 72.2
Drowsiness 2 503 29.1 28.0 30.1 2 285 42.4 35.8 49.0
Dizziness 3 737 22.4 1.3 33.9 13 3,132 9.3 5.4 14.1
Fatigue 3 737 13.3 0.9 20.9 3 781 13.2 0.4 28.9
Itching/rash 2 503 8.6 8.0 9.1 8 1,504 5.5 2.3 9.3
Nausea 3 737 7.8 2.1 12.6 12 3,058 12.9 6.4 20.2
Abdominal pain 3 737 7.2 3.0 9.4 19 3,495 33.4 22.6 43.9
Vomiting 3 737 6.8 1.7 9.6 15 2,911 7.9 3.8 13.2
Headache 3 737 4.4 0.4 6.7 17 3,314 16.6 9.8 24.0
Diarrhoea 3 737 4.3 2.6 6.3 16 3,106 12.1 6.5 19.3
Abbreviations: CI confidence interval
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between 40 and 60 mg/kg, for any Schistosoma species.
However, one should bear in mind the limitations of this
aggregate-data meta-analysis.
First, only five studies compared efficacy explicitly be-
tween age-groups [25, 26, 38, 52, 54]. Secondly, age trends
could not be calculated reliably because age categories as
reported in the papers are often broad and inconsistent
across studies, so that the calculated median age may not
reflect the range of responses within each individual
group. Following the WHO age classification for PC, the
preschool-aged children age-group should include 1–4-
year-olds and the school-aged group 5–14-year-olds.
Thirdly, preschool-aged children are under-represented:
11% of all subjects treated with PZQ 40 mg/kg. Lastly,
and importantly, methodology was insufficiently stan-
dardized: studies differed in terms of diagnostic approach
used (number of samples and smears), outcome measures
(CR, ERR using geometric or arithmetic mean), duration
of follow-up, and safety reporting. ERR was predominantly
calculated using geometric means, which are less apt to
identify outliers (patients responding less well) and tend
to show higher efficacy, compared to arithmetic means
or individual-patient response distributions [3, 69]. It is
therefore difficult to apply the WHO-recommended
threshold of 90% ERRam [3] to the results of these
studies and meta-analysis. Moreover, when the geometric
mean egg count was used, some studies calculated the
ERR using the geometric mean as the difference between
egg counts on all the patients, pre-treatment, and only the
positive subjects at the time of the endpoint assessment.
This method is inappropriate and biases the result be-
cause the denominator changes from the baseline to
the endpoint time, overestimates the egg counts post-
treatment and underestimates efficacy (in our calculations
here by ~ 24%).
To mitigate these shortcomings, we recalculated the
ERRgm and applied multivariate analyses. The predicted
ERRgm (pERRgm) provided a good fit with the reported
ERRgm using log-transformation; only three data points
(the lowest reported ERRgm) out of 34 fell well below
the trend line, which demonstrates a good regression fit.
Of these, two are from the same study (S. mansoni infec-
tion, moderate intensity, Kenya [62]). There might be
multiple reasons for this. One is mathematics (the geo-
metric mean wipes out extreme values, so the contribu-
tion of individual outliers in the response distribution to
the overall response is minimised). Another one is genetic
heterogeneity between schistosome populations from
different geographical regions, which means that other-
wise generalizable trends might not apply to some spe-
cific local situations. A third one is the background
prevalence of infection (which could not be estimated
here, but appears to play an important role [10]). Pre-
dicting ERRgm from CR has therefore its limitations,
but it allowed including a broader range of studies and
a larger number of subjects that would have otherwise
been possible, making it possible to expand the utility
and comparability of older studies; it is expected that
this will not be required with newer studies adopting
the WHO recommendation to express results as
ERRam [3].
With respect to the WHO-recommended threshold of
90% efficacy by ERRam, and with all the above-
mentioned provisos, using our statistical correction, we
found that 85% of the study arms treated with PZQ
40 mg/kg for any species would meet this criterion.
The multivariate analyses with random effect on the
study site to account for differences between studies
using PZQ 40 mg/kg in S. mansoni or S. haematobium
found no relationship between efficacy (whether mea-
sured as CR or ERR), and age (preschool vs school chil-
dren aged), duration of follow-up (one vs two months),
formulation (syrup vs tablet), diagnostic approach (single
vs multiple smears), and infection intensity (light vs
others). It is however worth noting that the effects of
risk factors on efficacy varied across individual studies.
Sousa-Figueiredo et al. (Uganda, S. mansoni) [26] found
that the risk of not clearing the infection was signifi-
cantly higher in children less than four years-old than
four to seven year-old by a factor of 3.5, and in children
with heavy infections by a factor of circa two. Thiong’o
et al. [62] (Kenya, 5–9, 10–14, 15+ years) found a signifi-
cant trend in four study sites for efficacy measured as
CR to decrease with age: ranging 59–92, 72–79, 80–93,
52–78%, and ERR ranging 99–100, 99–100, 93–98,
75–91); of note, older children were more heavily in-
fected and had higher ERRgm than younger children
with lower infection intensity before treatment. Gryseels
et al. [54] in Burundi found opposite trends in CRs after
treatment with doses of 20, 30 and 40 mg/kg in subjects
aged < 20 (from ~ 52 to 78%) and 20+ years (from 80 to
~ 94%). A recent study conducted on 508 Zimbabwean
children treated with PZQ 40 mg/kg for S. haematobium
not included in this review [70] found no difference in CR
and ERR between children aged one to five (both 100%)
and six to 10 years (94% and 97.9%, respectively). A previ-
ous systematic review and meta-analysis [10] which com-
pared CR in similar numbers of participants (1,026
preschool-aged and 12,906 school-aged children), also did
not detect significant differences in the combined CRs
for S. mansoni and S. haematobium (73.6 vs 71.1%,
respectively), but rather found a correlation between
lower CR and higher background infection prevalence,
especially for younger children. Here, we confirmed
and extended these findings by including also ERRgm
(see above), though both CR and ERRgm are probably
inaccurate for the reasons listed above. These disparate
findings likely reflect a range of situations in terms of
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infection prevalence and intensity in younger and older
children which also depends on the deployment and
coverage of preventive chemotherapy cycles in the
population.
These findings must be considered in the light of the
current imperfect test-of-cure; counting eggs in excreta
(using the available low-sensitivity methods) cannot dis-
tinguish between definitive (adult worm killing) and
temporary effects (suspended egg excretion). These
methods, while useful in quantifying effects of PC pro-
grammes at the population level, are inaccurate when it
comes to assess the real drug efficacy and detect early
signals of reduced efficacy and potential resistance.
The other question was whether higher levels of efficacy
could be achieved using 60 mg/kg instead of 40 mg/kg
(and in which age-group). No evidence of difference
emerged from this meta-analysis in children or previous
meta-analyses in overall population [12–14]. However, a
definitive conclusion cannot be reached on this question,
both because the numbers are relatively small (S. mansoni:
PZQ 40 mg/kg, n = 492 vs PZQ 60 mg/kg, n = 473; S.
haematobium: PZQ 40 mg/kg, n = 74 vs PZQ 60 mg/kg,
n = 77), and because ERRs do not capture the distribu-
tion of individual responses, and particularly outliers
[69]. We also know that better efficacy can be achieved
with longer treatment and higher doses - conditions
that are however not feasible in routine PC.
Compared to our previous systematic review and
meta-analysis, this was focused on the efficacy and safety
of PZQ in children; here, the calculated median age was
10 years old, and the range across all studies was one to
19 years, for a total of 14,340 subjects with an efficacy
outcome. The previous analysis (n = 19,499) had all
treatments and age-groups (age range 1–75 years old).
In addition, here we explored different approaches for
ERR calculations methods and applied a statistical cor-
rection to standardize ERR outcomes.
Praziquantel was well tolerated in all age groups,
though approximately half of the subjects experienced
an adverse event. It must be however noted that safety
was variably and inconsistently assessed; few AEs were
assessed systematically across most studies. The frequency
of certain AEs in each age-group may simply reflect the
fact that these were recorded in certain studies, and not
others. Also, it is very difficult to detect true signal from
background noise: the absence of pre-exposure informa-
tion on presence and severity of signs/symptom, prevents
assessing whether the events reported were related or not
to treatment. It is all-important that clinical researchers
be reminded of the critical relevance of collecting safety
information in the controlled environment of clinical
trials, even for drug which are widely regarded as well-
tolerated: this is especially true for drugs, like prazi-
quantel, that are used predominantly in children, who
might not complain and cannot verbalize discomfort,
with the risk of risks being underrated events being
underreported [71]. A simple way to doing that is to
collect and grade signs and symptoms at enrolment to
allow comparison between pre- and post-drug exposure,
to identify treatment-emergent signs and symptoms.
Child-friendly questionnaires including drawings should
be considered, especially in young children.
Conclusions
In summary, PZQ at the standard dose of 40 mg/kg was
generally effective at reducing intensity infection of all
Schistosoma species at all ages of those studied, but effi-
cacy varied across studies and age-ranges. This conclu-
sion should be tempered to reflect the above-mentioned
limitations and will require further studies and pooling
of data for an individual patient data meta-analysis. It is
indeed possible that exposure to infection and infection
intensity increase with age in the absence of effective
PC. This confounds analysis and makes it difficult to
conclude reliably as to whether the same PZQ dose
should be applied in preschool-aged children. It is also
worth mentioning that these conclusions have practical
implications for the solid oral form of praziquantel, as
other formulations are not recommended for use by the
WHO. This report also highlights the need for consistent
methodologies to be used in designing clinical trials for
schistosomiasis to assess and report on efficacy and safety.
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